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Objective: Patients with diabetes mellitus have an increased risk of coronary heart disease; however,
many patients with diabetes remain untreated or undertreated for coronary heart disease risk factors.
The incidence of type 2 diabetes is rapidly increasing in Taiwan. The aim of this study was to assess the
lipid-lowering effects of atorvastatin in Taiwanese diabetic patients with hyperlipidemia.
Materials and Methods: This 12-week open-label study, conducted at six hospitals in Taiwan, included 157
outpatients (aged 18e80 years old) with type 2 diabetes and concomitant hyperlipidemia. Individuals were
randomized (1:1:1) to three dosage groups, as follows: 52 patients received 10mgof atorvastatin per day; 52
patients received 20mgof atorvastatin per day; and the remaining 53patients received 40mgof atorvastatin
per day. Treatment targets were established according to the recommendations of the National Cholesterol
Education Program Adult Treatment Panel (NCEP ATP) III. The response was evaluated by Cochran-Mantel-
Haenszel tests. The change from the baseline level of all lipid parameters and high-sensitivity C-reactive
protein (hs-CRP) was determined through analysis of covariance and was assessed at each time point.
Results: The primary endpointda low-density lipoprotein-cholesterol (LDL-C) response of >100 mg/dL at
Week 12dwas achieved in a dose-dependent manner. The percentage of patients improving to this level
was higher in the 20 mg/day group (82%) and 40 mg/day group (82%) than in the 10 mg/day group (56%;
p ¼ 0.002). The percentage of patients achieving the more aggressive LDL-C goal of >70 mg/dL was 9.6%,
31.4%, and 47.1% in the 10 mg/day, 20 mg/day, and 40 mg/day groups, respectively (p < 0.001 in 10 mg/
day vs. 20 mg/day; p < 0.001 in 10 mg/day vs. 40 mg/day). The co-primary endpointethe percent change
from the baseline LDL-C levelealso increased in a dose-dependent manner: by 36.5% in the 10 mg/day
group; by 44.7% in the 20 mg/day group, and by 49.3% in the 40 mg/day group. For every 10 mg increase
in dose, an estimated 4.0% reduction in LDL-C and 3.5% reduction in total cholesterol could be achieved.
Triglyceride levels were also lowered, but there were no clinically meaningful changes in the level of
high-density lipoprotein-cholesterol or in hs-CRP. Fasting glucose and glycosylated hemoglobin levels
were not affected. Treatment-related adverse events were infrequent and mostly mild.
Conclusion: Atorvastatin is an effective and safe treatment for hyperlipidemia in Taiwanese diabetic
patients. Most patients taking the drug are able to achieve NCEP ATP III-recommended treatment targets
without any measurable effects on glycemic control.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.r.
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Recent studies show that the incidence of type 2 diabetes
mellitus (T2DM) is rapidly increasing in Taiwan, particularly in
younger age groups [1e4]. Patients with T2DM typically presentFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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heart disease (CHD). In fact, up to 80% of patients with diabetes die
prematurely from cardiovascular (CV) complications [5]. The de-
gree of CHD risk in diabetes mellitus (DM) patients without a
previous history of CHD is similar to that of patients with existing
CHD but without diabetes [6,7].
Cardiovascular risk factors for patients with diabetes can be
glucose-related (e.g., hyperglycemia and insulin resistance) or
related to other risk factors (e.g., dyslipidemia, hypertension, he-
mostatic abnormalities) [8]. Glycemic control is an integral part of
diabetes management; however, improving glycemic control alone
does not have a signiﬁcant impact on the cardiovascular disease
risk proﬁle of patients with diabetes [9e11]. Dyslipidemia has
emerged as an important, modiﬁable risk factor for CHD in patients
with T2DM or metabolic syndrome, thus highlighting the impor-
tance of lipid management [8,12]. Despite strong evidence for the
value of lowering lipid levels, dyslipidemia in many patients with
DM remains undertreated or untreated [13e15].
Management of dyslipidemia in diabetics requires a well-
rounded strategy that takes into account the full lipid proﬁle. The
American Diabetes Association (ADA) recognizes low-density li-
poprotein cholesterol (LDL-C) as the primary focus of lipid man-
agement in DM patients, based on evidence from lipid-lowering
clinical trials that demonstrate statistically signiﬁcant reductions in
CHD-related events [16]. The United Kingdom Prospective Diabetes
Study found that the LDL-C level is the best predictor of CHD, fol-
lowed by diastolic blood pressure, smoking, the high-density li-
poprotein-cholesterol (HDL-C) level, and glycemic control [17]. The
absolute concentrations of LDL-C in patients with diabetes are not
signiﬁcantly different from those in nondiabetic individuals;
however, patients with diabetes usually have a greater amount of
small, dense, atherogenic LDL particles, and may receive greater
reduction in the CHD risk than patients without diabetes [16]. The
current ADA and National Cholesterol Education ProgramdAdult
Treatment Panel III (NCEP ATP III)drecommended treatment goal
for individuals with diabetes is an LDL-C level of <100 mg/dL
[16,18]. However, levels <70 mg/dL have been advocated of late
[19,20].
Overwhelming evidence, including several landmark trials,
supports the effective reduction of LDL-C through the use of
hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase in-
hibitors (i.e., statins), which have been proven to reduce the risk
and the number of CV events in DM patients [21e26]. Atorvastatin
is highly effective in reducing LDL-C concentrations in a dose-
dependent manner in T2DM patients, while exerting no inﬂuence
on glycemic control [27e29].
No study has speciﬁcally examined the lipid-lowering potential
of atorvastatin in Taiwanese diabetic patients with hyperlipidemia.
The purpose of this study was to evaluate the efﬁcacy and safety of
a range of atorvastatin doses (10 mg/day, 20 mg/day, or 40 mg/day)
in this population, and to determine whether there were any
resultant effects on glycemic control. The NCEP ATP III goals for the
treatment of dyslipidemia in diabetes and the Taiwanese Bureau of
National Health Insurance guidelines were used.
2. Materials and methods
Between December 2, 2003 and October 28, 2004, this study
was conducted at six study centers in Taiwan in accordance with
the latest version of the Declaration of Helsinki (http://www.wma.
net/en/30publications/10policies/b3/) and the International Con-
ference on Harmonization Guideline for Good Clinical Practice
(http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_Products/
Guidelines/Efﬁcacy/E6_R1/Step4/E6_R1__Guideline.pdf). Indepen-
dent ethics committees at each participating center approved theprotocol (Pﬁzer study code: A2581123). Each study participant
provided written informed consent as a condition of entry.
2.1. Inclusion criteria
This study included male and female outpatients (aged 18e80
years old) who had T2DM in conjunction with the following:
hyperlipidemia; a glycosylated hemoglobin A1C (HbA1C) level of
10%; a LDL-C level of 130 mg/dL; and triglyceride (TG) levels of
<400 mg/dL. Women of childbearing age were required to use a
reliable method of birth control. Individuals were not eligible for
entry if they had secondary causes of hyperlipoproteinemia; type 1
diabetes mellitus; active liver disease; hypersensitivity to HMG-
CoA reductase inhibitors; a creatine kinase (CK) level >3.0  the
upper limit of normal (ULN), or a body mass index > 30.0 kg/m2.
Prohibited medications included immunosuppressive agents, lipid-
regulating or lipid-altering drugs, and other drugs that affect lipid
levels (including alternative medications or dietary supplements).
Individuals who took lipid-altering drugs were considered for
screening after a four-week washout period. The exceptionwas the
drug probucol, which must have been discontinued for at least six
months prior to considering an individual for screening.
2.2. Study design
This was a randomized, open-label, parallel group study of
atorvastatin for the treatment of hyperlipidemia in patients with
T2DM. Patients were assessed for ﬁve visits. The total duration of
the study, including screening, was 13 weeks. At Visit 1 (i.e.,
screening), study participants presented for eligibility assessment.
At Visit 2 (i.e., baseline), eligible participants were randomized (in a
ratio of 1:1:1) to 10 mg/day, 20 mg/day, or 40 mg/day atorvastatin
regimens. Thereafter, all participants were dosed for 12 weeks (i.e.,
the active treatment phase). During this period, three follow-up
visits were planned at intervals of 4 weeks (3 days). The partici-
pants were instructed to take the study medication in the evening
at the same time every day.
2.3. Measures
The screening included a full medical history that consisted of a
physical examination and vital signs, electrocardiography, labora-
tory testing, and serum lipid analysis. Concomitant medications,
compliance, and adverse events were also assessed and monitored
at each visit (except during the baseline visit when screening
measurements were used). All screening assessments were
repeated at the ﬁnal visit (Week 12). Blood samples were drawn
for laboratory testing (e.g., lipid analysis) after a minimum 12-
hour fast (water was allowed), and drawn between 6 hours and
18 hours after the last intake of the study drug. Serious adverse
events occurring up to 30 days after the end of treatment were
tracked.
2.4. Statistical analysis
Wedetermined that this studywould require a sample size of 50
individuals per dosage group (i.e., a total of 150 study participants).
There were two primary efﬁcacy variables: (1) the response change
from the baseline level and (2) the percent change in the LDL-C
level from the baseline level. A formal calculation of the sample
size was performed after taking both variables into consideration.
The study was designed with the assumption that 60%, 75%, and
90% of patients in the 10mg/day, 20mg/day, and 40mg/day groups,
respectively, would reach the speciﬁed LDL-C target of<100mg/dL.
By allowing an attrition rate of 10%, 50 patients per group would be
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a two-sided 5% signiﬁcance level (i.e., Chi-square test). This sample
size would also provide 80% power to detect a 5% difference be-
tween groups [i.e., with a common standard deviation (SD) of 15%]
for a mean percent change in LDL-C when tested at a two-sided 5%
signiﬁcance level [i.e., analysis of variance (ANOVA)].
Efﬁcacy variables were analyzed by using the intent-to-treat
(ITT) analysis population. If a post-baseline measure was missing
for a deﬁned visit, the last observation measured prior to that visit
was used by employing the last observation carried forward (LOCF)
methodology. The effect of treatment on the response [i.e., LDL-C
level <100 mg/dL or total cholesterol (TC) level <160 mg/dL] and
the trend of response (i.e., an increasing number of responders as
the dose increased) were evaluated by using the Cochran-Mantel-
Haenszel test (which is stratiﬁed by center) at the 5% signiﬁcance
level for each visit. The percent change in the level of lipids (i.e.,
LDL-C, TC, HDL-C, and TG) and highesensitivity C-reactive protein
(hs-CRP) from baseline to Week 4, Week 8, and Week 12 were
analyzed by using an ANOVA model. The treatment group, studyAssessed for eligib
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Fig. 1. Patient disposition. Analysis for safety is based on adverse events and laboratory test
baseline laboratory assessment was available. ITT ¼ intention-to-treat.center, and baseline values were the explanatory variables. For the
primary efﬁcacy variables, pair-wise comparisons were performed
between the 10 mg/day and the 20 mg/day groups, and between
the 10 mg/day and 40 mg/day groups (at a 2.5% signiﬁcance level).
To further assess the extent of the lipid-lowering effect of the drug,
additional post hoc analyses were undertaken. The number of pa-
tients achieving an LDL-C target of <70 mg/dL was measured.
Standard summaries of safety parameters, as deﬁned by the
sponsor’s worldwide safety standards, were generated for the
safety population (i.e., for all patients who took at least one dose of
the study medication). Compliance was calculated as the ratio of
the dose taken and the planned dose.
3. Results
Two hundred and ﬁfty-four study patients were screened for
entry; 155 of the patients were treated with a study medication,
and 138 (89%) of the 155 patients completed this study. Fig. 1
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Table 2
Low-density lipoprotein cholesterol and total cholesterol response rates in the
intention-to-treat analysis population.
Measure Atorvastatin dosage group
10 mg/day 20 mg/day 40 mg/day
LDL-C goal (<100 mg/dL)
Week 4/LOCFa 66 (33/50) 76 (39/51) 90 (45/50)
Week 8/LOCFa 63 (33/52) 84 (43/51) 84 (43/51)
Week 12/LOCFa 55.8 (29/52) 82.4 (42/51)b 82.4 (42/51)b
Baseline LDL-C  150 mg/dLa,c 36.0 (9/25) 78.8 (26/33) 82.1 (23/28)
Baseline HbA1C > 7%a,c 48.6 (18/37) 86.1 (31/36) 88.9 (32/36)
Baseline hs-CRP > 3 mg/Lc 64.7 (11/17) 70.6 (12/17) 85.7 (18/21)
LDL-C goal (<70 mg/dL)c
Week 12/LOCFa 9.6 (5/52) 31.4 (16/51)b 47.1 (24/51)b
Baseline LDL-C  150 mg/dLa 4.0 (1/25) 18.2 (6/33) 39.3 (11/28)
TC goal (<160 mg/dL)
Week 12/LOCFa 42 (22/52) 65 (33/51) 71 (36/51)
Data are presented as % (n/N).
HbA1C ¼ glycosylated hemoglobin; hs-CRP ¼ high sensitivity C-reactive protein;
ITT ¼ intention-to-treat; LDL-C ¼ low-density lipoprotein cholesterol; LOCF ¼ last
observation carried forward; n or N ¼ number (for subpopulation or total popula-
tion, respectively); TC ¼ total cholesterol.
a Indicates the response signiﬁcantly increased as the dose increased.
b Indicates a signiﬁcant difference (p < 0.001) compared to the 10 mg/day group.
c Based on post hoc analysis.
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dosage groups.
Groups were well-matched in demographic and baseline char-
acteristics (Table 1). The most common comorbidity present at
baseline was hypertension (50.3%), and the most frequently pre-
scribed concomitant medicationdapart from drugs used for dia-
betes (93.5%)dwere antihypertensive drugs (43.9%), which
consisted primarily of calcium channel blockers (21.3%), angio-
tensin II receptor blockers (20.0%), and angiotensin-converting
enzyme inhibitors (20.0%). At Week 12 (or LOCF), the primary ef-
ﬁcacy variable for the LDL-C response (i.e., a target level of
<100 mg/dL) was achieved in 55.8%, 82.4%, and 82.4% of patients
undergoing the 10 mg/day, 20 mg/day, and 40 mg/day atorvastatin
regimen, respectively (Table 2). At each visit, the LDL-C response
rate was signiﬁcantly increased at the higher doses. Table 2 shows
the ﬁndings of additional post hoc analyses of the LDL-C response
rates at Week 12 (or LOCF) by baseline subgroups (i.e., LDL-
C  150 mg/dL; HbA1c > 7%; and hs-CRP >3 mg/L), and shows the
proportion of participants who achieved themore aggressive LDL-C
goal of <70 mg/dL. The LDL-C goals were achieved by 9.6% of pa-
tients in the 10mg/day group, by 31.4% of patients in the 20 mg/day
group, and by 47.1% of patients in the 40 mg/day group. Therewas a
signiﬁcant difference in the LDL-C response between the 10mg/day
and the 20 mg/day groups, and between the 10 mg/day and 40 mg/
day groups (p < 0.001). The mean LDL-C was substantially reduced
from baseline toWeek 12 (or LOCF; Table 3). A signiﬁcant trend was
established at Week 12. We estimated that, in addition to the
reduction with the 10 mg/day dose of atorvastatin, each additional
10-mg dose increase would result in a 4.0% reduction in LDL-C
(p < 0.001; 95% CI 1.8%e6.2%). This translated into a pair-wise
difference of 8.2% between the 10 mg/day and 20 mg/day groups
(p ¼ 0.03), and a pair-wise difference of 12.7% between the 10 mg/
day and 40 mg/day groups (p < 0.001).
Similar to the ﬁndings for LDL-C, most patients achieved the
target TC response (i.e., a level<160mg/dL). Some patients attained
this level as early as Week 4 and sustained it with continued
treatment for the remainder of the study. This response was
signiﬁcantly greater at the higher doses, and this trend was true at
each visit (p  0.01). Substantial reductions in TC occurred at each
dose (Table 3). A signiﬁcant trend was established at Week 12. We
surmised that, in addition to the reduction observed with a 10 mg/
day dose of atorvastatin, each additional 10-mg dose increase
resulted in a 3.5% reduction in TC (p < 0.001; 95% CI 1.7%e5.2%).
The mean percent reduction in TG from the baseline level at
each visit was signiﬁcant for all groups (p < 0.05). The reduction in
the TG level was greater at the higher doses of atorvastatin;Table 1
Demographic and baseline characteristics.
Measure Atorvastatin dosage group
10 mg/day 20 mg/day 40 mg/day
(N ¼ 52) (N ¼ 51) (N ¼ 52)
Gender, female (%) 53.8 47.1 51.9
Age (y) 60.8 (11.4) 60.5 (10.5) 60.7 (9.8)
BMI (kg/m2) 24.8 (3.1) 25.7 (3.0) 25.6 (3.3)
Mean duration of diagnosis:
Diabetes mellitus
type 2, y
7.1 (0.1e22.0) 6.6 (0.1e24.0) 7.9 (0.1e25.0)
Hyperlipidemia, y 3.0 (0.0e10.5) 2.6 (0.0e11.3) 3.2 (0.1e8.3)
Presence of:
Hypertension 25 (48.1) 25 (49.0) 28 (53.8)
Diabetic retinopathy 4 (7.7) 9 (17.7) 6 (11.5)
Data are presented as n (%), mean (SD), or range, unless otherwise indicated.
BMI ¼ body mass index; n or N ¼ number (for subpopulation or total population,
respectively); SD ¼ standard deviation.however, there were no signiﬁcant differences or signiﬁcant trends
between the three groups at any visit (Table 3). The changes in the
HDL-C and hs-CRP levels varied for each dosage group, but there
was no consistent pattern of increase for the HDL-C level within any
group.
There were no clinically meaningful changes in HbA1C or fasting
glucose levels from the baseline to the end of the study. The levels
of HbA1C or fasting glucose were not particularly elevated in this
population (Table 3).
The incidence of treatment-related adverse events was 21.2% for
the 10 mg/day group, 15.7% for the 20 mg/day group, and 25% for
the 40 mg/day group. Thirty-two (20.6%) patients experienced
treatment-related adverse events. The most commonly reported
events were constipation (n ¼ 7) and an increase in the CK level
(n ¼ 6). Only one treatment-related adverse event (diarrhea) was
recorded as severe (Table 4). Of the six (3.9%) patients who had an
elevated CK level, two patients from the 40 mg/day group dis-
continued the study. Seven patients prematurely discontinued
treatment as a result of treatment-related adverse events, although
all events were mild (increased CK, n ¼ 2; dyspepsia, n ¼ 1;
myasthenia, n ¼ 1; dizziness, n ¼ 1; ﬂank pain and malaise, n ¼ 1;
constipation and ﬂatulence, n ¼ 1). Three patients experienced
serious medical events (e.g., fracture because of a fall, myocardial
infarction, and elevated blood pressure). However, these events
were not caused by the study drug. Two patients in the 10 mg/day
group experienced nontreatment-related mild myalgia. Changes in
the level of liver enzymes and in the blood pressure were minimal
and clinically comparable among the three groups. Physical ex-
amination ﬁndings generally showed no new abnormalities.
4. Discussion
Atorvastatin at doses of 10 mg/day, 20 mg/day, or 40 mg/day
effectively treated hyperlipidemia in Taiwanese patients with T2DM.
Most patients achievedNCEPATP III-recommended targets. Glycemic
control was not affected. The lipid parameters for LDL-C, TC, and TG
were signiﬁcantly reduced from the baseline level. Most patients
achieved a lipid-lowering response as early asWeek 4 and sustained
this response with continued treatment for the remainder of the 12
week study. Treatment-related adverse events were infrequent and
safety was not compromised with increasing doses.
Table 3
Change from baseline levels for lipids, high-sensitivity C-reactive protein, glycosylated hemoglobin, and fasting glucose in the intention-to-treat analysis population.
Measure Atorvastatin dosage group
10 mg/day 20 mg/day 40 mg/day
N ¼ 52 N ¼ 51 N ¼ 51
LDL-C (mmol/L)
Baseline 4.1 (0.62) 4.1 (0.46) 4.0 (0.51)
Week 12/LOCF 2.6 (0.68) 2.2 (0.75) 2.0 (0.68)
Percent changea (95% CI) 36.5 (31.9 e 41.2)b 44.7 (40.0 e 49.4)b 49.3 (44.6 e 54.0)b
TC (mmol/L)
Baseline 6.1 (0.70) 6.0 (0.63) 6.0 (0.64)
Week 12/LOCF 4.5 (0.88) 4.0 (0.92) 3.7 (0.83)
Percent changea (95% CI) 26.5 (22.7 e 30.2)b 33.3 (29.5 e 37.0)b 37.5 (33.7 e 41.2)b
TG (mmol/L)
Baseline 1.8 (0.78) 1.7 (0.59) 1.6 (0.72)
Week 12/LOCF 1.5 (0.71) 1.3 (0.49) 1.1 (0.43)
Percent changea (95% CI) 11.7 (4.2 e 19.3)b 18.0 (10.4 e 25.6)b 21.6 (14.0 e 29.2)b
HDL-C (mmol/L)
Baseline 1.2 (0.26) 1.2 (0.31) 1.2 (0.26)
Week 12/LOCF 1.2 (0.24) 1.2 (0.25) 1.2 (0.29)
Percent changea (95% CI) 3.2 (e2.6 e 8.9)c 1.4 (e4.4 e 7.1)c 3.5 (e9.3 e 2.3)c
hs-CRP (mg/L)
Baseline 2.9 (3.7) 4.0 (9.3) 3.3 (3.5)
Week 12/LOC 2.6 (4.5) 2.1 (2.5) 3.1 (6.1)
Percent changea (95% CI) 60.6 (62.0 e 183.2)c 4.3 (e128.1 e 119.5)c 107.8 (e15.8 e 231.4)c
HbA1c (%)d
Baseline 8.9 (1.7) 8.7 (1.3) 9.0 (1.3)
Week 12/LOCF 8.7 (1.7) 8.9 (1.5) 9.4 (1.7)
Fasting glucose (mmol/L)d
Baseline 8.9 (2.8) 8.6 (2.1) 8.7 (2.0)
Week 12/LOCF 8.1 (2.3) 8.9 (2.6) 9.1 (2.4)
Data are presented as mean (SD) unless otherwise indicated.
CI ¼ conﬁdence interval; HbA1C ¼ glycosylated hemoglobin; HDL-C ¼ high-density lipoprotein cholesterol; hs-CRP ¼ high sensitivity C-reactive protein; ITT ¼ intention-to-
treat; LDL-C ¼ low-density lipoprotein cholesterol; LOCF ¼ last observation carried forward; SD ¼ standard deviation; TC ¼ total cholesterol; TG ¼ triglyceride.
a Least squares estimates of the presented mean percent change.
b Changes are signiﬁcant compared to baseline.
c Changes are not signiﬁcant compared to baseline.
d Based on post hoc analysis.
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treatment groups was 73% (i.e., 113 of 154 patients); this portion of
the ITT population achieved the NCEP ATP III LDL-C goal of
<100 mg/dL with a portion of patients achieving the target at
higher doses. As treating to target is the recommended standard of
care, it is signiﬁcant that atorvastatin helped patients achieve tar-
gets across the dose range. Our ﬁndings are particularly meaningfulTable 4
Treatment-related adverse events in the safety analysis population.
Measure Atorvastatin dosage group
10 mg/day 20 mg/day 40 mg/day
N ¼ 52 N ¼ 51 N ¼ 52
Total no. of treatment-related
adverse events (n)
15 8 15
Total no. of patients with
treatment-related adverse
events
11 (21.2) 8 (15.7) 13 (25.0)
Adverse events experienced
by more than one patient
Alanine aminotransferase
increased
1 (1.9) 1 (2.0) 2 (3.8)
Aspartate aminotransferase
increased
1 (1.9) 1 (2.0) 1 (1.9)
Constipation 3 (5.8) 1 (2.0) 3 (5.8)
Creatine kinase increased 2 (3.8) d 4 (7.7)
Dyspepsia d 2 (3.9) d
Diarrhea 1 (1.9) d 1 (1.9)a
Data are presented as n (%).
a Recorded as severe; however, the patient recovered.because only 35.3% of diabetic individuals (n ¼ 7541) reached goals
of total cholesterol (i.e.,<160mg/dL) or LDL-C (i.e.<100mg/dL) in a
national diabetes quality survey conducted in 2006 [14]. In the
Diabetes Atorvastatin Lipid Intervention (DALI) study [27] 71.2% of
patients in the atorvastatin 10 mg/day group and 84.7% of patients
in the atorvastatin 80 mg/day group achieved ADA treatment goals
after 30 weeks. The 10 mg/day dose of atorvastatin was not as
successful in our study; however, over a shorter period of time, the
40 mg/day dose in our patients achieved similar results as the
80 mg/day group in the DALI study. In the Collaborative Atorvas-
tatin Diabetes Study (CARDS) [30]dthe ﬁrst and largest primary
prevention study to assess statins solely in patients with T2DM
(n ¼ 2838)dan impressive 75% of patients randomized to ator-
vastatin (at 10 mg/day) achieved LDL-C levels of <2.5 mmol/L with
25% of the patients reaching levels of <1.7 mmol/L during the 3.9-
year treatment phase of the study.
When treating to target, starting with lower doses and titrating
up to achieve the target may be a better approach. However, it has
been recommended that lipid-lowering treatment should adopt a
more aggressive approach to prevent CHD. In the Atorvastatin Goal
Achievement Across Risk Levels (ATGOAL) study conducted in
Thailand (n¼ 242), most study participants (88.8%) achieved LDL-C
goals at Week 8, and nearly all patients reached LDL-C target levels
by Week 2 and Week 4 (81.6% and 87.1%, respectively) [29].
A post hoc analysis revealed that 29% (45 of 154) of the patients
in the ITT population reached the more stringent LDL-C goal of
<70 mg/dL. This response was greater at the higher doses of ator-
vastatin. A substantial number of patients who had a baseline LDL-C
level of 150 mg/dL reached this goal. The NCEP ATP III and ADA
C.-T. Chang et al. / Tzu Chi Medical Journal 25 (2013) 168e174 173guidelines both agree that a LDL-C level of less than 100 mg/dL is
the minimum goal, and should not be considered the level needed
to achieve themaximum beneﬁt of reducing the LDL-C level. Recent
updates to these guidelines suggest aggressive therapy to achieve a
LDL-C level of <70 mg/dL [16,20]. However, this has not been
investigated thoroughly. The Pravastatin or Atorvastatin Evaluation
and Infection TherapydThrombolysis in Myocardial Infarction 22
(PROVE-IT TIMI 22) study adopted the more stringent goal of
lowering the LDL-C level to approximately 70 mg/dL, and indicated
a relative risk reduction of 16% at 2 years (p¼ 0.05; 95% CI, 5%e26%)
at the primary endpoint (i.e., death, myocardial infarction, docu-
mented unstable angina requiring hospitalization, coronary revas-
cularization, or stroke); 37% of the study participants in the PROVE
IT TIMI 22 study had diabetes [31]. This may serve as a reference for
future studies and clinical practice.
In the current study, we surmised thatdin addition to the
reduction in LDL-C occurring with the administration of 10 mg/day
atorvastatindeach additional 10-mg increase in the dose would
result in a further 4% reduction in the LDL-C level. The combined
overall reduction in the LDL-C level for the entire population
moreover was 44%. Irrespective of speciﬁed targets, the absolute
reduction in the LDL-C level is a crucial component in lipid-
lowering treatment because it has been proven that any reduc-
tion in the LDL-C level results in a comparable reduction in CHD
risk, irrespective of the baseline LDL-C level [19,20]. Because of a
signiﬁcant risk of CV events in patients with diabetes, statin therapy
is warranted as part of the ﬁrst-line therapy, even when LDL-C
levels are only mildly elevated.
The CARDS study provided convincing support for previous evi-
dence indicating potential CV beneﬁts with statin therapy in patients
who have T2DM but no history of CHD. The study found a 37%
relative risk reduction in the incidence of CV events with an overall
40% reduction in the LDL-C level from the baseline level [30].
In the PROVE IT study, intensive atorvastatin (80 mg) lipidlow-
ering therapy resulted in a 17% risk reduction in the diabetes sub-
group (n ¼ 770) [32]. The Treating to New Targets (TNT) study
similarly found that a daily dose of 10 mg atorvastatin reduced the
LDL-C level by 34% and a daily dose of 80 mg atorvastatin reduced
the LDL-C level by 49%. Both doses subsequently resulted in a 22%
reduction in CV morbidity [33]. The Anglo-Scandinavian Cardiac
Outcomes TrialeLipid Lowering Arm (ASCOT-LLA) study further-
more found an insigniﬁcant 16% reduction in CHD in 2532 patients
with diabetes and hypertension who had no previous CHD [26].
There have been similar ﬁndings with other statins [23]. All studies
validate the concept that a greater reduction in the LDL-C level
signiﬁcantly reduces CV morbidity.
There was minimal, if any, increase in the HDL-C level over the
12-week treatment period. A low HDL-C level has been associated
with a greater risk of vascular events (31.1% greater risk, compared
to a placebo) , suggesting that strategies targeting low HDL-C levels
may have a CV beneﬁt [23].
However, results for HDL-C vary from study to study. Only a 1%
increase in the HDL-C level was observed during the CARDS study
[30]. By contrast, the HDL-C level was signiﬁcantly increased in the
DALI study: 6% of study participants receiving the 10 mg/day dose
of atorvastatin and 5.2% receiving the 80 mg/day dose of atorvas-
tatin had a marked elevation in their HDL-C levels [27]. If HDL-C
levels are lower than 0.9 mmol/L, adding a selective cholesterol
inhibitor (e.g., ezetimibe), or a low-dose bile acid sequestrant is a
useful strategy because these therapies increase the HDL-C level
and induce a greater reduction in the LDL-C level. Ezetimibe can
induce an additional 15e20% reduction in the LDL-C level [34]. The
HDLeAtherosclerosis Treatment Study (HATS) found that simva-
statin plus niacin increased the HDL-C level by 26% in patients with
diabetes whose baseline HDL-C levels were <0.9 mmol/L [35].However, theremay be increased safety risks in regard tomyopathy
and liver toxicity when such combination strategies are used [18].
Inﬂammation is a pivotal ﬁnal step in acute coronary syndrome.
Several studies show that measuring hs-CRP (a nonspeciﬁc but
sensitive marker of underlying systemic inﬂammation) in stable
individuals is highly predictive of CV events [36]. Patients with
diabetes and metabolic syndrome reportedly have elevated hs-CRP
levels [37]. Concentrations of hs-CRP of <1 mg/L indicate a low risk
for future CV events; concentrations of 1e3 mg/L indicate a mod-
erate risk; and concentrations > 3 mg/L indicate a high risk [38]. In
our study, we found that most patients on entry had hs-CRP con-
centrations indicating a moderate to high risk for future CV events:
55 patients were at high risk, 54 patients were at moderate risk,
and 45 patients were at low risk. The mean hs-CRP concentration
for the entire population was 3.4 mg/L. Despite the evidence that
atorvastatin can lower hs-CRP to <1 mg/L, we found that the
change in the hs-CRP level wasminimal, although therewas a trend
towards reduction. However, no statistical signiﬁcance was
observed. The hs-CRP data for this study was indeed extremely
variable. Other factors that have an effect on inﬂammation (e.g.,
hypertension, retinopathy, smoking, obesity) may need to be
considered when interpreting serum hs-CRP levels in patients with
diabetes.
Adverse events were infrequent and mostly mild in this study.
No patient experienced an extreme elevation of the CK level (pre-
speciﬁed at >10 the ULN), and there were no cases of rhabdo-
myolysis or myopathy reported during the study. Statins are
associated with a small increased risk of elevating liver enzyme
levels and an increased frequency of myopathy. However, adverse
events were generally mild and infrequent [23,30]. Periodic
monitoring of liver function tests and CK is recommended, partic-
ularly when high-dose statin therapy is used. However, it is widely
accepted that the longterm beneﬁts of statin therapy outweigh the
reasonably low risk of adverse events [19].
For the most part, patients with diabetes are less than optimally
treated for the management of CV risk. Dyslipidemia is asymptom-
atic until a CV event occurs; therefore compliance with lipid-
lowering regimens is a challenge because of poor awareness of the
threat. Leiter reported that only 59% of physicians aim for the target
LDL-C level of <100 mg/dL in patients with no previous CVD,
compared with 84% for patients with CVD [13]. Because CVD is a top
priority risk concern for patients with diabetes, the overall risk of
CVD events should be the key consideration when making decisions
about aggressively treating diabetic dyslipidemiawith statin therapy.
When baseline LDL-C levels are mildly above the current goal (115e
125mg/dL), a 30e40% reduction in LDL-C should be a prudent target.
More stringent goals (e.g., <70 mg/dL) are warranted in diabetic
patients with CVD, based on the CV risk. The choice of high-dose
statin therapy should therefore depend principally on the LDL-C
reduction needed to reach the target level, on the initial LDL-C
level, and on the judgment of the physician in charge.
The current study has some limitations. First, it used an open-
label design, which is not as rigorous as a blinded design. Howev-
er, the primary endpoint for this study was based on the objective
measure of lipid sampling. A longer study may be necessary to
determine the longterm CV beneﬁts of atorvastatin in this popu-
lation. The link between lipid-lowering treatment and CV outcomes
is nevertheless well documented in many patient populations.
Second, all secondary endpoints were tested at an unadjusted 5%
level of signiﬁcance, the purpose of which was to supplement ev-
idence from conﬁrmatory primary analysis to fully characterize the
clinical effects of treatment. All ﬁndings should therefore be
interpreted in this context. In conclusion, because the incidence of
diagnosed T2DM has markedly increased in Taiwan in recent years,
the ﬁndings from this study can provide useful information for
C.-T. Chang et al. / Tzu Chi Medical Journal 25 (2013) 168e174174reference when managing hyperlipidemia in Taiwanese patients
with T2DM.
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